Entero Therapeutics Inc reports results for the quarter ended in June 30 - Earnings Summary

GridAI Technologies

21/10/2024 23:13

* Entero Therapeutics Inc  ENTO.OQ  reported a quarterly
adjusted
loss of $3.37​​ per share for the quarter ended June 30, higher
than the same quarter last year, when the company reported EPS
of $-37.80.  The mean expectation of two analysts for the
quarter was for a loss of $1.55 per share. 
    * Reported revenue was zero​; analysts expected zero. 
    * Entero Therapeutics Inc's reported EPS for the quarter was
a
loss of $3.86​.
    * The company reported a quarterly loss of $8.85 million.
    * Entero Therapeutics Inc shares had risen by 114.7% this
quarter and lost 82.4% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is  "hold."

Wall Street's median 12-month price target for Entero
Therapeutics Inc is $36.00 
This summary was machine generated from LSEG data October 21 at
10:13 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2024      -1.55          -3.37          Missed
 Mar. 31 2024      -2.43          -0.64          Beat
 Dec. 31 2023      -4.03          -5.35          Missed
 Sep. 30 2023      -12.30         -9.20          Beat